At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 1,137 enrolled
Drug / intervention
Bimatoprost 0.01%drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study of LUMIGAN® RC in the Clinical Setting
In Brief
A Phase 4 clinical trial evaluating Bimatoprost 0.01% for Glaucoma, Primary Open Angle and Ocular Hypertension. Completed, enrolled 1,137 participants across 1 site.
Detailed Summary
This study will evaluate bimatoprost 0.01% (LUMIGAN® RC) in patients with elevated intraocular pressure (IOP) due to primary open angle glaucoma (POAG) or ocular hypertension (OHT) in a clinical setting.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Primary Open Angle, Ocular Hypertension
CountriesCanada
Collaborators--
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2009
Primary CompletionMar 2011
First PostedApr 2013
TodayJul 2026
First PostedApr 17, 2013
Enrollment StartDec 1, 2009
Primary CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 13.2 years ago
Interventions
Bimatoprost 0.01%drug
Bimatoprost 0.01% (LUMIGAN® RC) administered as one drop in the study eye(s) each evening for 12 weeks.